Earnings Report - Agilent Technologies, Inc. is set to release its fourth-quarter earnings results on November 25, with analysts expecting earnings of $1.41 per share, an increase from $1.38 per share in the same period last year [1] - The company is projected to report quarterly revenue of $1.67 billion, slightly down from $1.69 billion a year earlier [1] Analyst Ratings - Evercore ISI Group analyst Vijay Kumar has maintained an In-Line rating for Agilent and raised the price target from $135 to $145 [2] - The company currently offers an annual dividend yield of 0.75%, translating to a quarterly dividend of 24.8 cents per share [2] Dividend Calculations - To achieve a monthly dividend income of $500, an investor would need to own approximately 6,048 shares of Agilent, equating to a total investment of about $798,699 [3] - For a more conservative monthly income goal of $100, an investor would need to hold 1,210 shares, requiring an investment of around $159,793 [3] Stock Performance - Shares of Agilent increased by 2.7%, closing at $132.06 on Thursday [6]

Agilent Technologies Inc (NYSE:A) is scheduled to release fourth-quarter financial results after the close on Monday, Nov. 25. Analysts expect the medical research name to report earnings of $1.41 per share -- a 2.2% year-over-year increase -- on revenue of $1.67 billion.Looking back on its past eight post-earnings performances, A's history of next-day returns are split, with four positive and four negative. The equity averaged a move of 5.3%, regardless of direction in the last two years, and the options p ...

In its upcoming report, Agilent Technologies (A) is predicted by Wall Street analysts to post quarterly earnings of $1.41 per share, reflecting an increase of 2.2% compared to the same period last year. Revenues are forecasted to be $1.67 billion, representing a year-over-year decrease of 0.9%.Over the last 30 days, there has been no revision in the consensus EPS estimate for the quarter. This signifies the covering analysts' collective reconsideration of their initial forecasts over the course of this time ...

Agilent Technologies (A) boosts its LSAG segment with the launch of the Agilent InfinityLab Liquid Chromatography (LC) Series portfolio, comprising the 1290 Infinity III LC, 1260 Infinity III Prime LC and 1260 Infinity III LC systems.The new Agilent InfinityLab Assist Technology is being used for the first time in these High Performance Liquid Chromatography systems, providing enhanced system assistance.These systems have a significant impact on task automation, connectivity, predictive feedback and error r ...

Core Insights - Agilent Technologies reported Q3 fiscal 2024 earnings of $1.32 per share, exceeding estimates by 5.6%, but down 8% year-over-year [2] - Revenues reached $1.58 billion, surpassing the consensus estimate of $1.56 billion, but declined 5.6% year-over-year [2] - The company faced broad-based weakness across several markets, including Pharma, Food, Chemical, and Academic sectors, with weak momentum in China [2] Financial Performance - Life Sciences & Applied Markets Group (LSAG) generated $782 million, down 8% year-over-year, missing the consensus estimate of $849 million [3] - Agilent Cross Lab Group (ACG) revenues were $411 million, exceeding the consensus of $385 million, with a 4% year-over-year increase [3] - Diagnostics and Genomics Group (DGG) revenues decreased 9% year-over-year to $385 million, beating the consensus of $332 million [4] Operating Results - Gross margin for LSAG expanded by 10 basis points to 60.2%, while ACG's gross margin increased by 120 basis points to 52.1% [5] - DGG's gross margin contracted by 170 basis points to 51.8% [5] - Operating margin for Q3 was 21.1%, significantly up from 7.9% in the prior year [5][6] Balance Sheet - As of July 31, 2024, cash and cash equivalents were $1.78 billion, up from $1.67 billion in April 2024 [7] - Accounts receivables were $1.23 billion, slightly down from $1.25 billion in the previous quarter [7] - Long-term debt remained stable at $2.137 billion [7] Guidance - For Q4 fiscal 2024, management expects revenues between $1.641 billion and $1.691 billion, indicating a potential decline of 2.8% to an increase of 0.2% year-over-year [8] - Fiscal 2024 revenue guidance revised to $6.45-$6.50 billion, reflecting a decline of 5.6-4.9% year-over-year [8] - Non-GAAP earnings per share guidance for fiscal 2024 adjusted to $5.21-$5.25 [8] Market Sentiment - Recent estimates for Agilent have been trending downward, indicating a shift in market sentiment [9] - The stock currently holds a Zacks Rank 3 (Hold), suggesting an expectation of in-line returns in the coming months [11]

Agilent Technologies Inc. NYSE: A is a diversified global leader in the life sciences, diagnostics, and applied chemical markets. The company provides equipment systems, instruments, software and services that enable researchers and scientists to make breakthroughs in the medical sector and various fields. While its many segments are experiencing pullbacks in the end market, its top growth segment is being driven by solutions to address polyfluoroalkyl substances (PFAS), otherwise known as forever chemicals ...

In this articleAIR-FRAGEBAAALTULSA, Okla. — Parts and labor shortages. Delayed deliveries of new airplanes from Boeing and Airbus. An engine recall. Premature repairs. It's all piling up, and aircraft engine shops around the world are overflowing. As travelers boarded planes in record numbers this summer, airline executives waited anxiously for repairs and overhauls of their engines.The repair and overhaul of engines has swelled from a $31 billion business before the pandemic to $58 billion this year, accor ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (MARK ONE) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For the quarterly period ended July 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. For transition period from to Commission File Number: 001-15405 AGILENT TECHNOLOGIES, INC. (Exact Name of registrant as specified in its charter) Delaware 77-0518772 (State or other jurisd ...

Have you assessed how the international operations of Agilent Technologies (A) performed in the quarter ended July 2024? For this scientific instrument maker, possessing an expansive global footprint, parsing the trends of international revenues could be critical to gauge its financial resilience and growth prospects.The global economy today is deeply interlinked, making a company's engagement with international markets a critical factor in determining its financial success and growth path. It has become es ...

hapabapa Agilent Technologies (NYSE:A) offers instruments, consumables, software and services to life sciences, diagnostics and applied chemical markets. Agilent has made significant efforts in transforming its business towards growth areas including biopharma, polyfluoroalkyl substances (PFAS) testing and advanced materials for semiconductor. I am initiating a ‘Buy’ rating with a one-year target price of $160 per share. Growing Biopharma, PFAS & Advanced Materials Agilent offers workflow solutions for ...